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STEROIDS have an acknowledged place in the therapy of the haematological
complications of lymphoid tumours. Their place in producing tumour regression
and in alleviating toxicity is less well defined and has been little discussed in the
British literature.
This paper describes experience gained in treating with steroids a group of
thirty-four patients who had diffuse lymphoid tumours. An attempt is made to
assess the value of steroids in producing tumour regression and subjective im-
provement at a late stage in the disease.
MATERIALS AND METHODS
The patients attended the reticulosis clinic of the hospital and were admitted
for in-patient treatment as required. All had evidence ofdiffuse disease and were
usually toxic and febrile. Many had been treated previously with alkylating
agents or radiotherapy and many were unsuitable for further therapy in this way
because of thrombocytopenia.
Two preparations were used: prednisolone and betamethasone. Twenty-two
patients received 40 mg. prednisolone daily; four patients received 80 mg.
prednisolone daily; and eight patients received betamethasone, 8 mg. daily.
Where a response to treatment occurred, this was assessed as either " sub-
jective " where the patient felt definitely better with lessening of malaise, fatigue,
sw-eating and improvement in appetite, or " objective ", where there was definite
evidence of tumour regression.
Haematological improvement was not included in this assessment.
RESULTS
Table I indicates the different pathological groups into which the treated
patients fell and the response to treatment in each group.
It will be seen that six patients showed objective improvement but in only
three ofthese patients was this improvement marked. Each ofthese six patients
experienced subjective improvement. A further seven patients had subjective
benefit alone. Twenty-one patients showed no response to treatment.
There were no particular features, clinical or pathological, which distinguished
the three patients who showed marked tumour regression from the remaining
thirty-one patients, and their response to treatment is at present inexplicable.
Two short case histories illustrate the occasional marked response to steroids.B. M. GRODEN AND M. G. DUNNIGAN
TABLE I.-Distribution of Patients and the Numbers Showing Improvement
Number ofpatients
showing improvement
Objective
Number of and Subjective
Disease patients Subjective only
Hodgkin's disease . 21 . 2 6
Lyinphosarcoma . 8 . 2 0
Reticulosarcoma . 2 . 0 0
Reticulum cell . 1 . 0 1
sarcoma
Chronic lymphatic . 2 . 2 0
leukaernia
Total 34 . 6 7
Case 1
A twenty-one year old man was admitted in December, 1961, with generalised
adenopathy, fever, sweating, malaise and anaemia. A gland biopsy showed the
changes of Hodgkin's disease.
He was treated with betamethasone 8 mg. per day and within three days there
were marked lessening of toxicity and diminution of adenopathy. The dose of
steroid was reduced to 4 mg. daily and he was discharged. He continued to
improve, at home, and when seen two weeks later his adenopathy had disappeared.
He was maintained on betamethasone 1-5 mg. daily but he relapsed after nine
months with a return of toxicity, lymphadenopathy and splenomegaly. When
the dose of betamethasone was increased to 8 mg. per day, there was again
marked improvement. His toxicity disappeared in three days and his adeno-
pathy had cleared after one week. The dose was again gradually reduced to 3
mg. per day and he remains well six months later on this dose, without evidence of
toxicity, adenopathy or splenomegaly.
Case 2
A forty year old male presented with cervical adenopathy in September.
1957. A gland biopsy revealed the changes of Hodgkin's disease.
He was treated with local radiotherapy, the glands regressed and he remained
well for three months when he began to have malaise, anorexia, profuse sweating
and exertional dyspnoea. Physical examination revealed only small glands in
both axillae and groins but he looked unwell. Haemoglobin was 13*3 g./100 ml.,
white count 3000/cu.mm; a chest X-ray was negative.
It was felt that his symptoms were due to Hodgkin's disease and he was
started on prednisolone 40 mg. daily. There was subjective benefit within forty-
eight hours with diminution in night sweats, improvement in appetite and lessen-
ing of exertional dyspnoea. After one month his dose of prednisolone was re-
duced to 20 mg. daily and he felt and looked well for a further two months. After
this period his symptoms ofgeneral toxicity returned as before without evidence of
tumour. When his dose of steroid was increased to 30 mg. per day, there was
marked subjective improvement within a few days, a return ofappetite andenergy,
and decrease in night sweats, so that he was again able to resume work. He
remained well for a further six months when he relapsed into the terminal stage
of his illness.
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DISCUSSION
These results indicate that in only six of the patients in our series (18 per
cent) did steroid therapy produce tumour regression. A further seven (21 per
cent) experienced subjective relief alone. It can be said, therefore, that thirteen
(39 per cent) of these patients benefited from steroid therapy.
Pearson et al. (1949) first drew attention to the fact that cortisone and ACTH
could produce lymphoid tumour regression while Straus et al. (1952) found that
one patient of a group of ten patients with Hodgkin's disease exhibited tumour
regression on cortisone 100 mg. daily. Spurr and Wilson (1955) however found
no evidence of tumour regression in their non-leukaemic patients.
These results tend to agree with our own experience and differ substantially
from those of Kofman et al. (1962) who reported that 53 per cent of their group
of patients with malignant lymphomas experienced tumour regression when
treated with doses of prednisolone varying from 30-1000 mg. daily. Their
results may indicate that the response of these tumours is dependent on the dose
ofsteroid exhibited and that the doses used in our series were too small. We were
unable to correlate response with the dose of steroid used in our cases.
Subjective improvement is more difficult to assess since it is difficult to exclude
placebo effects and the euphoria induced in some patients by steroids. These
possibilities might account for the improvement in some of our patients, but in
several the improvement was so marked, with lessening of sweating, fever and
malaise that we feel that in some ill-defined way the treatment has affected the
toxicity which is a feature ofthe late stages oflymphoid tumours. Improvement
with steroids is unfortunately not lasting as with all forms oftreatment ofadvanced
lymphoid tumours. This is shown by survival figures which indicate that only
five of the patients who improved were alive one year after starting treatment.
We feel that the response of lymphoid tumours to steroids is inferior to the
results obtained with alkylating agents such as nitrogen mustard, tumour regres-
sion and lessening of toxicity being more consistently obtained with the latter.
Apart from the well-known haematological complications, steroids would seem
justified mainly when alkylating agents are contra-indicated because of marrow
depression. The occasional marked objective improvement and the moderate
symptomatic improvement in about a third of the patients treated in our series
might also indicate that steroids are worthy of trial in the late stages oflymphoid
tumours as an adjunct to therapy with cytotoxic drugs and radiotherapy.
SUMMARY
Experience in treating with steroids a group of thirty-four patients with lym-
phoid tumours is reported. Subjective improvement occurred in thirteen of the
patients, of whom six exhibited tumour regression.
Previous similar reports are discussed and it is suggested that results may
depend on the dosage used.
It is considered that although inferior to alkylating agents, steroids have a
definite place in the treatment of lymphoid tumours.
We would like to express our gratitude to Dr. Alexander Brown for helpful
advice in the writing of this paper.
581582 B. M1. GROI)EN AND AI. G. DUNNIGAN
REFERENCES
KOFMAN, S.. PERLIA, C. P.. BOESEN, E., EISENSTEIN. R. AND TAYLOR, S. (1962)
Cancer, 15, 338.
PEARSON, 0. H.. ELIEL, L. P.. RAWSON, R. W., DOBRINER. K. AND RHOADS. C. P.-
(1949) Cancer, 2, 943.
SPURR. C. L. ANTD WILSON, W. L.-(1955) Sth. med. J., Birmingham, Ala., 48, 1335.
STRAUSS, B.. JACOBSON. A. S., BERSON, S. A., BERNSTEIN, T. C., FADEM, R. S. AND
YALOW. R. S. (1952) Amer. J. Med., 12 170